Study of survivin and X-linked inhibitor of apoptosis protein (XIAP) genes in acute myeloid leukemia (AML)

Study of survivin and X-linked inhibitor of apoptosis protein (XIAP) genes in acute myeloid leukemia (AML)

Apoptosis deregulation is important for cancer development, chemotherapy response, and prognosis. Survivin and X-linked inhibitor of apoptosis protein (XIAP) are 2 members of the inhibitor of apoptosis proteins family (IAP). We used semi-quantitative reverse transcriptase polymerase chain reaction (...

Full description

Saved in:
Bibliographic Details
Published in:Laboratory hematology Vol. 18; no. 1; p. 1
Main Authors: Ibrahim, Azza Mostafa, Mansour, Iman Maher, Wilson, Manal Michel, Mokhtar, Doha Abdel-Hamid, Helal, Amani Mohamed, Al Wakeel, Hanan Mohamed
Format: Journal Article
Language:English
Published: United States 01-03-2012
Subjects:
Adolescent
Adult
Case-Control Studies
Female
Gene Expression
Humans
Induction Chemotherapy
Inhibitor of Apoptosis Proteins - genetics
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - mortality
Male
Middle Aged
Prognosis
Treatment Outcome
X-Linked Inhibitor of Apoptosis Protein - drug effects
X-Linked Inhibitor of Apoptosis Protein - genetics
Young Adult
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Apoptosis deregulation is important for cancer development, chemotherapy response, and prognosis. Survivin and X-linked inhibitor of apoptosis protein (XIAP) are 2 members of the inhibitor of apoptosis proteins family (IAP). We used semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to determine the levels of expression of survivin and XIAP in 30 patients with de novo acute myeloid leukemia (AML) and 20 age- and sex-matched healthy volunteers. Survivin and XIAP overexpression were detected in 36.7% and 43.3% of cases, respectively. Patients with overexpression of either survivin or XIAP showed unfavorable response to chemotherapy in 81.2% and 91.7%, respectively. Also, these cases showed shorter median survival time (30 days) compared to patients with normal expression of either survivin or XIAP (150 days and 180 days). Patients with overexpression of both survivin and XIAP showed unfavorable response to induction therapy in 100% of the patients and the shortest median survival (30 days). These findings suggest that survivin and XIAP may have a role in leukemogenesis and provide prognostic information.
ISSN:1523-6528
DOI:10.1532/lh96.11005